Henry Ford Hospital researchers have identified for the first time two molecules that hold promise as a biomarker for measuring cartilage damage associated with osteoarthritis. Researchers say the concentration of two molecules called non-coding RNAs in blood were associated with mild cartilage damage in 30 patients who were one year removed from reconstruction surgery to repair an anterior cruciate ligament, or ACL, injury. The findings are described as significant in the ongoing and tedious search of biomarkers for osteoarthritis, the most common form of arthritis that afflicts an estimated 27 million Americans aged 25 and older. It is caused by the normal aging process or wear and tear of a joint. The study was being presented Saturday at the annual Orthopaedic Research Society in San Francisco.
Experts from the Department of Orthopaedic Surgery at NYU Langone Medical Center are presenting their latest research and clinical findings on diseases of the muscle, tendon, bone and joint at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS), February 7-11 in San Francisco, California. "The introduction of new imaging and research techniques, combined with advances in clinical care, allows our researchers to identify the basic biology of joint tissues and the impact of functional decline due to aging and the onset of osteoarthritis, " said Joseph Zuckerman, MD, the Walter A. L. Thompson Professor of Orthopaedic Surgery, chair of the Department of Orthopaedic Surgery at NYU Langone Medical Center and past-president of AAOS. "As a result we are able to bring basic science discoveries directly to the bedside and use advanced bioengineering techniques to promote tissue regeneration and improve long-term patient results.
New research presented at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) highlights the benefits of total knee replacement (TKR) in elderly patients with osteoarthritis, including a lower probability of heart failure and mortality. Investigators reviewed Medicare records to identify osteoarthritis patients, separating them into two groups - those who underwent TKR to relieve symptoms, and those who did not. Outcomes of interest included average annual Medicare payments for related care, mortality, and new diagnoses of congestive heart failure, diabetes and depression. Differences in costs and risk ratios were adjusted for multiple variables including age, sex, race and region. The results (adjusted for underlying health conditions) were compared at fixed periods of one year, three years, five years and seven years after surgery.
Around 7.5 million Americans, which is about 2.2% of the population, suffer from psoriaris, an autoimmune disease causing red, flaky skin. A new review in the Journal of the American Academy of Orthopedic Surgeons (JAAOS) reveals that patients with psoriatic arthritis (PsA), a type of arthritis that affects nearly 48% of patients with the skin disease psoriasis, gain substantial benefits from medications or biologic agents that target T-cells, white blood cells involved in the body's immune system. Lead study author Michael S. Day, M.D., MPhil, a resident orthopedic surgeon with the Department of Orthopedic Surgery at NYU Hospital for Joint Diseases explains: "Although these new immunosuppressive agents are expensive, they are the only agents that have demonstrated a decrease in radiologic progression of peripheral arthritis, and can be used to manage associated types of inflammation, as well as skin and nail disease.
A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults. The preventive therapy will "optimize care for hemophilia patients of all ages by stopping unexpected bleeding events that can have a detrimental impact on the lives of patients, " said Dr. Leonard Valentino, director of the Rush Hemophilia and Thrombophilia Center and principal investigator on the study. The study results appeared in the January online version of the Journal of Thrombosis and Haemostasis. Valentino is associate professor of Pediatrics at Rush University's Rush Medical College. The study, sponsored by Baxter Healthcare Corporation, was conducted as part of a comprehensive clinical study of ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM) to compare the effectiveness of two prophylactic treatment regimens, as well as between on-demand and prophylaxis treatments, in preventing bleeding in previously treated patients with severe or moderately severe hemophilia A.